Does the media refer more to CYRX or LAB?

In the previous week, CryoPort had 9 more articles in the media than Standard BioTools. MarketBeat recorded 14 mentions for CryoPort and 5 mentions for Standard BioTools. CryoPort's average media sentiment score of 0.27 beat Standard BioTools' score of -0.42 indicating that CryoPort is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 5 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Standard BioTools 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, LAB or EVO?

Standard BioTools has higher earnings, but lower revenue than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Standard BioTools $85.33M 3.65 -$74.90M $0.22 3.60 Evotec $891.97M 0.85 -$117.12M N/A N/A

Is LAB or EVO more profitable?

Standard BioTools has a net margin of 100.36% compared to Evotec's net margin of -26.20%. Standard BioTools' return on equity of -7.57% beat Evotec's return on equity. Company Net Margins Return on Equity Return on Assets Standard BioTools 100.36% -7.57% -6.14% Evotec -26.20% -24.93% -11.35%

Does the media prefer LAB or EVO?

In the previous week, Evotec had 2 more articles in the media than Standard BioTools. MarketBeat recorded 7 mentions for Evotec and 5 mentions for Standard BioTools. Evotec's average media sentiment score of 0.02 beat Standard BioTools' score of -0.42 indicating that Evotec is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Standard BioTools 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Evotec 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LAB or DNA?

In the previous week, Ginkgo Bioworks had 6 more articles in the media than Standard BioTools. MarketBeat recorded 11 mentions for Ginkgo Bioworks and 5 mentions for Standard BioTools. Ginkgo Bioworks' average media sentiment score of 0.37 beat Standard BioTools' score of -0.42 indicating that Ginkgo Bioworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Standard BioTools 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ginkgo Bioworks 1 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MLAB or LAB?

In the previous week, Standard BioTools had 2 more articles in the media than Mesa Laboratories. MarketBeat recorded 5 mentions for Standard BioTools and 3 mentions for Mesa Laboratories. Mesa Laboratories' average media sentiment score of 0.67 beat Standard BioTools' score of -0.42 indicating that Mesa Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesa Laboratories 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Standard BioTools 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LAB or CTKB?

In the previous week, Cytek Biosciences had 3 more articles in the media than Standard BioTools. MarketBeat recorded 8 mentions for Cytek Biosciences and 5 mentions for Standard BioTools. Cytek Biosciences' average media sentiment score of 0.52 beat Standard BioTools' score of -0.42 indicating that Cytek Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Standard BioTools 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cytek Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Standard BioTools (LAB) Competitors

$0.79 -0.01 (-0.88%)

As of 10:27 AM Eastern

Compare

LAB vs. CYRX, EVO, DNA, MLAB, and CTKB

Should you buy Standard BioTools stock or one of its competitors? MarketBeat compares Standard BioTools with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Standard BioTools include CryoPort (CYRX), Evotec (EVO), Ginkgo Bioworks (DNA), Mesa Laboratories (MLAB), and Cytek Biosciences (CTKB). These companies are all part of the "life sciences tools & services" industry.

How does Standard BioTools compare to CryoPort?

CryoPort (NASDAQ:CYRX) and Standard BioTools (NASDAQ:LAB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

In the previous week, CryoPort had 9 more articles in the media than Standard BioTools. MarketBeat recorded 14 mentions for CryoPort and 5 mentions for Standard BioTools. CryoPort's average media sentiment score of 0.27 beat Standard BioTools' score of -0.42 indicating that CryoPort is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Standard BioTools	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Standard BioTools has a net margin of 100.36% compared to CryoPort's net margin of -20.05%. CryoPort's return on equity of -7.20% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	-20.05%	-7.20%	-4.30%
Standard BioTools	100.36%	-7.57%	-6.14%

92.9% of CryoPort shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 9.5% of CryoPort shares are held by company insiders. Comparatively, 26.8% of Standard BioTools shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CryoPort has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market.

CryoPort presently has a consensus price target of $18.00, suggesting a potential upside of 21.98%. Standard BioTools has a consensus price target of $1.35, suggesting a potential upside of 70.24%. Given Standard BioTools' higher probable upside, analysts clearly believe Standard BioTools is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

CryoPort has higher revenue and earnings than Standard BioTools. CryoPort is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.24	$78.30M	-$0.90	N/A
Standard BioTools	$85.33M	3.65	-$74.90M	$0.22	3.60

Summary

CryoPort beats Standard BioTools on 11 of the 16 factors compared between the two stocks.

How does Standard BioTools compare to Evotec?

Standard BioTools (NASDAQ:LAB) and Evotec (NASDAQ:EVO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Standard BioTools has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33M	3.65	-$74.90M	$0.22	3.60
Evotec	$891.97M	0.85	-$117.12M	N/A	N/A

In the previous week, Evotec had 2 more articles in the media than Standard BioTools. MarketBeat recorded 7 mentions for Evotec and 5 mentions for Standard BioTools. Evotec's average media sentiment score of 0.02 beat Standard BioTools' score of -0.42 indicating that Evotec is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Standard BioTools	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evotec	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

53.7% of Standard BioTools shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 26.8% of Standard BioTools shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Standard BioTools has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, Evotec has a beta of 1.96, suggesting that its share price is 96% more volatile than the broader market.

Standard BioTools has a net margin of 100.36% compared to Evotec's net margin of -26.20%. Standard BioTools' return on equity of -7.57% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	100.36%	-7.57%	-6.14%
Evotec	-26.20%	-24.93%	-11.35%

Standard BioTools presently has a consensus target price of $1.35, suggesting a potential upside of 70.24%. Evotec has a consensus target price of $3.00, suggesting a potential upside of 41.51%. Given Standard BioTools' higher probable upside, equities analysts clearly believe Standard BioTools is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Evotec	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Standard BioTools beats Evotec on 8 of the 14 factors compared between the two stocks.

How does Standard BioTools compare to Ginkgo Bioworks?

Standard BioTools (NASDAQ:LAB) and Ginkgo Bioworks (NYSE:DNA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

Standard BioTools currently has a consensus price target of $1.35, suggesting a potential upside of 70.24%. Ginkgo Bioworks has a consensus price target of $7.00, suggesting a potential downside of 15.35%. Given Standard BioTools' stronger consensus rating and higher probable upside, research analysts clearly believe Standard BioTools is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Ginkgo Bioworks	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

Standard BioTools has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market.

In the previous week, Ginkgo Bioworks had 6 more articles in the media than Standard BioTools. MarketBeat recorded 11 mentions for Ginkgo Bioworks and 5 mentions for Standard BioTools. Ginkgo Bioworks' average media sentiment score of 0.37 beat Standard BioTools' score of -0.42 indicating that Ginkgo Bioworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Standard BioTools	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ginkgo Bioworks	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Standard BioTools has a net margin of 100.36% compared to Ginkgo Bioworks' net margin of -259.96%. Standard BioTools' return on equity of -7.57% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	100.36%	-7.57%	-6.14%
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%

53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 26.8% of Standard BioTools shares are owned by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Standard BioTools has higher earnings, but lower revenue than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33M	3.65	-$74.90M	$0.22	3.60
Ginkgo Bioworks	$170.15M	3.17	-$312.76M	-$5.01	N/A

Summary

Standard BioTools beats Ginkgo Bioworks on 10 of the 15 factors compared between the two stocks.

How does Standard BioTools compare to Mesa Laboratories?

Mesa Laboratories (NASDAQ:MLAB) and Standard BioTools (NASDAQ:LAB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Mesa Laboratories has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market.

Standard BioTools has a net margin of 100.36% compared to Mesa Laboratories' net margin of 2.69%. Mesa Laboratories' return on equity of 20.96% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesa Laboratories	2.69%	20.96%	8.78%
Standard BioTools	100.36%	-7.57%	-6.14%

90.6% of Mesa Laboratories shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 2.8% of Mesa Laboratories shares are owned by company insiders. Comparatively, 26.8% of Standard BioTools shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Mesa Laboratories has higher revenue and earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesa Laboratories	$249.13M	2.28	$6.71M	$1.20	84.55
Standard BioTools	$85.33M	3.65	-$74.90M	$0.22	3.60

Mesa Laboratories presently has a consensus target price of $94.00, suggesting a potential downside of 7.35%. Standard BioTools has a consensus target price of $1.35, suggesting a potential upside of 70.24%. Given Standard BioTools' higher possible upside, analysts clearly believe Standard BioTools is more favorable than Mesa Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesa Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Standard BioTools had 2 more articles in the media than Mesa Laboratories. MarketBeat recorded 5 mentions for Standard BioTools and 3 mentions for Mesa Laboratories. Mesa Laboratories' average media sentiment score of 0.67 beat Standard BioTools' score of -0.42 indicating that Mesa Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesa Laboratories	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Standard BioTools	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Mesa Laboratories beats Standard BioTools on 8 of the 14 factors compared between the two stocks.

How does Standard BioTools compare to Cytek Biosciences?

Standard BioTools (NASDAQ:LAB) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

Standard BioTools has a net margin of 100.36% compared to Cytek Biosciences' net margin of -38.98%. Standard BioTools' return on equity of -7.57% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	100.36%	-7.57%	-6.14%
Cytek Biosciences	-38.98%	-12.40%	-9.17%

53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 26.8% of Standard BioTools shares are owned by insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Standard BioTools currently has a consensus target price of $1.35, indicating a potential upside of 70.24%. Cytek Biosciences has a consensus target price of $5.56, indicating a potential upside of 30.42%. Given Standard BioTools' higher possible upside, analysts plainly believe Standard BioTools is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Cytek Biosciences had 3 more articles in the media than Standard BioTools. MarketBeat recorded 8 mentions for Cytek Biosciences and 5 mentions for Standard BioTools. Cytek Biosciences' average media sentiment score of 0.52 beat Standard BioTools' score of -0.42 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Standard BioTools	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytek Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytek Biosciences has higher revenue and earnings than Standard BioTools. Cytek Biosciences is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33M	3.65	-$74.90M	$0.22	3.60
Cytek Biosciences	$201.49M	2.75	-$66.54M	-$0.62	N/A

Standard BioTools has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market.

Summary

Standard BioTools beats Cytek Biosciences on 9 of the 16 factors compared between the two stocks.

Get Standard BioTools News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LAB vs. The Competition

Export

Metric	Standard BioTools	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$309.35M	$9.49B	$7.02B	$12.96B
Dividend Yield	N/A	1.45%	2.58%	10.20%
P/E Ratio	3.58	63.00	269.90	24.97
Price / Sales	3.65	104.75	659.13	107.89
Price / Cash	N/A	26.16	28.89	37.44
Price / Book	0.72	5.16	11.29	6.44
Net Income	-$74.90M	$56.66B	$3.45B	$347.50M
7 Day Performance	-8.45%	2.75%	3.56%	3.82%
1 Month Performance	-13.65%	-0.38%	-0.57%	-0.37%
1 Year Performance	-39.23%	22.61%	77.67%	23.81%

Standard BioTools Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LAB Standard BioTools	3.2764 of 5 stars	$0.79 -0.9%	$1.35 +70.2%	-38.7%	$309.35M	$85.33M	3.58	620	Earnings Report Analyst Downgrade
CYRX CryoPort	3.2073 of 5 stars	$15.23 -1.7%	$16.38 +7.5%	+100.0%	$767.09M	$176.18M	11.27	1,186	Earnings Report Analyst Forecast
EVO Evotec	3.7267 of 5 stars	$1.95 +0.5%	$3.00 +53.8%	-49.1%	$693.73M	$891.97M	N/A	4,553	Upcoming Earnings Gap Up
DNA Ginkgo Bioworks	0.7343 of 5 stars	$9.31 +4.1%	$8.50 -8.7%	-34.9%	$607.87M	$170.15M	N/A	640	Earnings Report Analyst Downgrade
MLAB Mesa Laboratories	1.4075 of 5 stars	$102.43 -1.9%	$94.00 -8.2%	+59.7%	$576.66M	$249.13M	85.81	680

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LAB) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Standard BioTools (LAB) Competitors

LAB vs. CYRX, EVO, DNA, MLAB, and CTKB

How does Standard BioTools compare to CryoPort?

Summary

How does Standard BioTools compare to Evotec?

Summary

How does Standard BioTools compare to Ginkgo Bioworks?

Summary

How does Standard BioTools compare to Mesa Laboratories?

Summary

How does Standard BioTools compare to Cytek Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LAB vs. The Competition

Standard BioTools Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Standard BioTools (LAB) Competitors

LAB vs. CYRX, EVO, DNA, MLAB, and CTKB

How does Standard BioTools compare to CryoPort?

Does the media refer more to CYRX or LAB?

Is CYRX or LAB more profitable?

Do insiders & institutionals hold more shares of CYRX or LAB?

Which has more risk & volatility, CYRX or LAB?

Do analysts rate CYRX or LAB?

Which has preferable earnings and valuation, CYRX or LAB?

Summary

How does Standard BioTools compare to Evotec?

Which has stronger earnings & valuation, LAB or EVO?

Does the media prefer LAB or EVO?

Do institutionals & insiders hold more shares of LAB or EVO?

Which has more volatility and risk, LAB or EVO?

Is LAB or EVO more profitable?

Do analysts recommend LAB or EVO?

Summary

How does Standard BioTools compare to Ginkgo Bioworks?

Do analysts rate LAB or DNA?

Which has more risk & volatility, LAB or DNA?

Does the media refer more to LAB or DNA?

Is LAB or DNA more profitable?

Do insiders & institutionals have more ownership in LAB or DNA?

Which has stronger valuation and earnings, LAB or DNA?

Summary

How does Standard BioTools compare to Mesa Laboratories?

Which has more risk and volatility, MLAB or LAB?

Is MLAB or LAB more profitable?

Do institutionals & insiders have more ownership in MLAB or LAB?

Which has higher earnings & valuation, MLAB or LAB?

Do analysts prefer MLAB or LAB?

Does the media prefer MLAB or LAB?

Summary

How does Standard BioTools compare to Cytek Biosciences?

Is LAB or CTKB more profitable?

Do institutionals & insiders believe in LAB or CTKB?

Do analysts rate LAB or CTKB?

Does the media refer more to LAB or CTKB?

Which has higher earnings and valuation, LAB or CTKB?

Which has more risk & volatility, LAB or CTKB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LAB vs. The Competition

Standard BioTools Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools